Loading...
•
Sep 30, 2023
Repligen Q3 2023 Earnings Report
Repligen's third quarter results reflected resilience amidst industry challenges, marked by strengthened orders and strategic acquisitions.
Key Takeaways
Repligen reported a decrease in total revenue to $141.2 million compared to $200.7 million in Q3 2022. The company saw positive signs of recovery with a book-to-bill ratio of 1.07. They narrowed their full year revenue guidance to $635-$645 million.
Total third quarter revenues were reported at $141.2 million, with base business revenues of $140.1 million.
The company's order book strengthened, achieving a total book-to-bill ratio of 1.07.
Repligen acquired Metenova AB on October 2, expanding their Fluid Management offering.
Full year revenue guidance was narrowed to a range of $635-$645 million.
Revenue by Segment
Forward Guidance
Repligen narrowed its full year 2023 revenue guidance to a range of $635M-$645M. The guidance includes the impact of FlexBiosys and Metenova acquisitions and excludes the impact of potential additional acquisitions, and future fluctuations in foreign currency exchange rates.
Positive Outlook
- Revenue guidance maintained at $635M-$645M.
- Base business revenue expected to decline by 8.5%-9.5%.
- Gross margin projected at 45.5%-46.5%.
- Operating margin anticipated to be 10%-11%.
- Net income forecasted at $72M-$75M.
Challenges Ahead
- Year-over-year change in revenue expected to be (19.5%)-(21%).
- COVID-Related Revenue estimated at $30M.
- Income from Operations projected at $61M-$65M.
- Tax Rate on Pre-Tax Income estimated at 12%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...